From GlobeNewswire:

Zymeworks Inc. will have management participate in investor conferences in February 2024. This includes the 6th Annual Biotechnology Conference, the 34th Annual Healthcare Life Sciences Conference, and Citi’s Virtual Oncology Leadership Summit. The company is dedicated to developing multifunctional biotherapeutics for the treatment of difficult-to-treat diseases, focusing on cancers and other diseases. Zymeworks has also started global clinical trials for zanidatamab, a HER2-targeted bispecific antibody. For more information about Zymeworks, visit www.zymeworks.com or follow @ZymeworksInc on X. For investor inquiries, reach out to Shrinal Inamdar at [email protected] or for media inquiries, contact Diana Papove at [email protected].



Read more: Zymeworks Announces Participation in Upcoming Investor